{"id":"NCT01197560","sponsor":"Celgene","briefTitle":"Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)","officialTitle":"A Phase 2/3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Lenalidomide (Revlimid Â®) Versus Investigator's Choice in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2010-09-02","primaryCompletion":"2013-07-04","completion":"2018-04-05","firstPosted":"2010-09-09","resultsPosted":"2014-08-20","lastUpdate":"2019-11-25"},"enrollment":111,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diffuse Large B-cell Lymphoma"],"interventions":[{"type":"DRUG","name":"Lenalidomide","otherNames":[]},{"type":"DRUG","name":"Gemcitabine","otherNames":[]},{"type":"DRUG","name":"Oxaliplatin","otherNames":[]},{"type":"DRUG","name":"Rituximab","otherNames":[]},{"type":"DRUG","name":"Etoposide","otherNames":[]}],"arms":[{"label":"Lenalidomide","type":"EXPERIMENTAL"},{"label":"Investigators Choice","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to compare lenalidomide to a control drug and see which one delays Diffuse Large B-Cell Lymphoma (DLBCL) disease progression longer.","primaryOutcome":{"measure":"Stage 1: Percentage of Participants With an Overall Response According to the International Working Group (IWG) Response Criteria for Non Hodgkin's Lymphoma (NHL), Cheson 1999 and Evaluated by the Independent Response Adjudication Committee (IRAC)","timeFrame":"From the date of randomization to the data cut-off of 4 July 2013; when all patients reached the scheduled 16-week assessment or had progressed/died before the scheduled 16-week assessment); the median study duration was 27.0 and 19.7 weeks, respectively.","effectByArm":[{"arm":"Lenalidomide","deltaMin":27.5,"sd":null},{"arm":"Investigators Choice (IC)","deltaMin":11.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.079"},{"comp":"OG001","p":"0.279"},{"comp":"OG001","p":"0.179"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":57,"countries":["United States","Australia","Austria","Czechia","France","Italy","Spain","Sweden","United Kingdom"]},"refs":{"pmids":["28381416","21495023"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":31,"n":54},"commonTop":["ANAEMIA","NEUTROPENIA","FATIGUE","DIARRHOEA","PYREXIA"]}}